Substance / Medication

Dorzolamide hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Pigmentary glaucoma

Open-angle glaucoma

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Comparing the effects and safety of dorzolamide hydrochloride + timolol maleate versus brimonidine after neodymium-doped yttrium aluminium garnet laser capsulotomy posterior capsule opacification.

Çakmak Kaan, Erbil Hasan, Mesci Cem et al. · Eur J Ophthalmol · 2022

PMID: 34791912RCT

Effects of perioperative topical dorzolamide hydrochloride-timolol maleate administration on incidence and severity of postoperative ocular hypertension in dogs undergoing cataract extraction by phacoemulsification.

Matusow Rachel B, Herring Ian P, Pickett J Phillip et al. · J Am Vet Med Assoc · 2016

PMID: 27767427RCT

The additive effect of dorzolamide hydrochloride (Trusopt) and a morning dose of bimatoprost (Lumigan) on intraocular pressure and retrobulbar blood flow in patients with primary open-angle glaucoma.

Stankiewicz Andrzej, Wierzbowska Joanna, Siemiatkowska Anna et al. · Br J Ophthalmol · 2010

PMID: 20558428RCTFull text (PMC)

Effect of dorzolamide hydrochloride on central corneal thickness in humans with cornea guttata.

Wirtitsch Matthias G, Findl Oliver, Heinzl Harald et al. · Arch Ophthalmol · 2007

PMID: 17923541RCT

Three-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugs.

Inoue Kenji, Shiokawa Minako, Sugahara Michitaka et al. · Jpn J Ophthalmol · 2012

PMID: 23001284Trial

Intraocular pressure and ocular hemodynamics in patients with primary open-angle glaucoma treated with the combination of morning dosing of bimatoprost and dorzolamide hydrochloride.

Stankiewicz Andrzej, Misiuk-Hojło Marta, Grabska-Liberek Iwona et al. · Acta Ophthalmol · 2011

PMID: 21223530Trial

[Double-masked, phase III comparative study of the combination ophthalmic solution of the 1% dorzolamide hydrochloride/0.5% timolol maleate (MK-0507A) in patients with glaucoma and ocular hypertension].

Kitazawa Yoshiaki, Araie Makoto, [object Object] · Nippon Ganka Gakkai Zasshi · 2011

PMID: 21735753Trial

Assessment of retinal hemodynamics with the Canon laser blood flowmeter after a single dose of 2% dorzolamide hydrochloride eyedrops.

Faingold Dana, Hudson Chris, Flanagan John et al. · Can J Ophthalmol · 2004

PMID: 15491034Trial

Short-term effect of dorzolamide hydrochloride on central corneal thickness in humans with cornea guttata.

Wirtitsch Matthias G, Findl Oliver, Kiss Barbara et al. · Arch Ophthalmol · 2003

PMID: 12742838Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Dorzolamide hydrochloride (substance)
SNOMED CT: 126154004
UMLS CUI: C0771293

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.